Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) CFO Pamela Wapnick sold 6,265 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $2.88, for a total transaction of $18,043.20. Following the sale, the chief financial officer now owns 63,051 shares of the company’s stock, valued at $181,586.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Metagenomi Trading Down 6.2 %
NASDAQ MGX opened at $2.72 on Friday. Metagenomi, Inc. has a fifty-two week low of $2.63 and a fifty-two week high of $12.74. The stock has a 50 day simple moving average of $3.81 and a two-hundred day simple moving average of $6.76.
Metagenomi (NASDAQ:MGX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.30. The business had revenue of $20.01 million during the quarter, compared to analysts’ expectations of $14.80 million. On average, sell-side analysts expect that Metagenomi, Inc. will post -3.04 earnings per share for the current year.
Institutional Investors Weigh In On Metagenomi
Wall Street Analyst Weigh In
MGX has been the subject of a number of recent research reports. BMO Capital Markets lowered their target price on Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Metagenomi in a research note on Friday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Metagenomi in a research note on Thursday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $15.50.
View Our Latest Report on Metagenomi
Metagenomi Company Profile
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Stories
- Five stocks we like better than Metagenomi
- How to Use Stock Screeners to Find Stocks
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What is Put Option Volume?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Want to Profit on the Downtrend? Downtrends, Explained.
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.